ESMO 2025: Belzutifan Demonstrates Tumor Reduction and Symptom Relief in Patients with Rare Neuroendocrine Tumors
In a landmark advancement for the treatment of rare neuroendocrine tumors, researchers have reported groundbreaking results with the oral HIF-2α ...
